Fig 1: A single intratumoral treatment with IL-31–neutralizing antibody reduces CTCL-induced pruritus.(A) Number of scratching bouts in 1 hour. Compared with IgG control antibody, IL-31–neutralizing antibody significantly reduced scratching at 1 hour, 3 hours, 5 hours, and 24 hours. Two-way ANOVA, P < 0.0001, F(1, 78)= 162.9. (B) Alloknesis induced by von Frey filament. Compared with IgG control antibody, IL-31–neutralizing antibody significantly reduced CTCL-induced alloknesis at 1 hour and 3 hours. Two-way ANOVA; P < 0.0001, F(1, 72)= 40.09. n = 6 for control IgG treatment; n = 9 for IL-31 antibody treatment. Behavior was assessed on CTCL day 25. **P < 0.01 and ****P < 0.0001, by Bonferroni’s multiple-comparison test.
Fig 2: The IL-31 signaling pathway is upregulated and critically contributes to pruritus after CTCL.(A–C) Triple staining showing Nissl-labeled neurons (A), Il31ra mRNA (RNAscope, red, B), and Trpv1 mRNA (RNAscope, green, C) at different phases of CTCL. Scale bars: 60 μm. (D) Enlarged images from the boxed areas in C. Original magnification, ×20. Note the increase in DRG neurons expressing Il31ra after CTCL. Also note that Il31ra is heavily colocalized with Trpv1 in the same DRG neurons of naive and CTCL mice. (E) Quantitative analysis showing the percentage of Il31ra+ DRG neurons in naive and CTCL mice (n = 4). P < 0.0001 versus naive, 1-way ANOVA, F(3, 12)= 62.77. (F and G) Percentage of double-labeled neurons in the Il31ra (F) and Trpv1 (G) populations. n = 4 animals. P < 0.0001 versus naive, 1-way ANOVA, F(3, 12)= 0.1945 (F), F(3, 12)= 20.25 (G). (H) ELISA results showing low levels of IL-31 in nonmalignant control skin tissue (n = 5, with acute Myla cell inoculation) and significantly higher levels of IL-31 in CTCL day-60 lymphoma-bearing skin tissue (n = 8). **P < 0.01 and ****P < 0.0001, versus control, unpaired, 2-tailed Student’s t test, t = 2.929, df = 11.
Supplier Page from Abcam for Human IL-31 ELISA Kit